Nxera Pharma Co., Ltd. (TYO:4565)
Japan · Delayed Price · Currency is JPY 1,212.00
-30.00 (-2.42%)
May 12, 2026, 3:30 PM JST
Nxera Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 34,227 | 29,615 | 28,835 | 12,766 | 15,569 | 17,712 | |
Revenue Growth (YoY) | 10.88% | 2.71% | 125.87% | -18.00% | -12.10% | 100.32% |
Cost of Revenue | 7,701 | 8,198 | 7,616 | 3,102 | 926 | 933 |
Gross Profit | 26,526 | 21,417 | 21,219 | 9,664 | 14,643 | 16,779 |
Selling, General & Admin | 15,094 | 11,773 | 12,924 | 8,167 | 3,535 | 3,138 |
Research & Development | 13,686 | 14,466 | 11,816 | 10,075 | 7,454 | 5,931 |
Other Operating Expenses | 771 | -5 | 12 | 23 | - | -2 |
Operating Expenses | 29,551 | 29,686 | 27,843 | 20,063 | 11,831 | 9,869 |
Operating Income | -3,025 | -8,269 | -6,624 | -10,399 | 2,812 | 6,910 |
Interest Expense | -7,513 | -845 | -769 | -787 | -673 | -518 |
Interest & Investment Income | 845 | 971 | 1,478 | 1,225 | 236 | 4 |
Earnings From Equity Investments | -57 | - | - | - | -429 | 50 |
Currency Exchange Gain (Loss) | - | 16 | 27 | -329 | 313 | 22 |
Other Non Operating Income (Expenses) | -1 | -5,015 | 1,288 | -282 | 696 | -3,105 |
EBT Excluding Unusual Items | -9,751 | -13,142 | -4,600 | -10,572 | 2,955 | 3,363 |
Merger & Restructuring Charges | - | -636 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | 1 | -46 | -1,877 | 208 |
Gain (Loss) on Sale of Assets | - | -12 | -63 | -62 | - | - |
Asset Writedown | - | -1,160 | - | - | - | -3,138 |
Pretax Income | -9,751 | -14,950 | -4,662 | -10,680 | 1,078 | 433 |
Income Tax Expense | 226 | -2,420 | 176 | -3,487 | 696 | -584 |
Earnings From Continuing Operations | -9,977 | -12,530 | -4,838 | -7,193 | 382 | 1,017 |
Net Income | -9,977 | -12,530 | -4,838 | -7,193 | 382 | 1,017 |
Net Income to Common | -9,977 | -12,530 | -4,838 | -7,193 | 382 | 1,017 |
Net Income Growth | - | - | - | - | -62.44% | -31.24% |
Shares Outstanding (Basic) | 90 | 90 | 90 | 83 | 82 | 81 |
Shares Outstanding (Diluted) | 90 | 90 | 90 | 83 | 83 | 82 |
Shares Change (YoY) | 0.65% | 0.61% | 8.74% | -0.09% | 0.71% | 3.16% |
EPS (Basic) | -110.33 | -138.80 | -53.92 | -87.17 | 4.67 | 12.53 |
EPS (Diluted) | -110.34 | -138.80 | -53.92 | -87.18 | 4.63 | 12.40 |
EPS Growth | - | - | - | - | -62.66% | -33.30% |
Free Cash Flow | -5,578 | -3,116 | -8,244 | -6,077 | 9,675 | 6,902 |
Free Cash Flow Per Share | -61.69 | -34.52 | -91.87 | -73.65 | 117.14 | 84.17 |
Gross Margin | 77.50% | 72.32% | 73.59% | 75.70% | 94.05% | 94.73% |
Operating Margin | -8.84% | -27.92% | -22.97% | -81.46% | 18.06% | 39.01% |
Profit Margin | -29.15% | -42.31% | -16.78% | -56.34% | 2.45% | 5.74% |
Free Cash Flow Margin | -16.30% | -10.52% | -28.59% | -47.60% | 62.14% | 38.97% |
EBITDA | 1,360 | -3,903 | -2,640 | -7,921 | 4,157 | 8,188 |
EBITDA Margin | 3.97% | -13.18% | -9.16% | -62.05% | 26.70% | 46.23% |
D&A For EBITDA | 4,385 | 4,366 | 3,984 | 2,478 | 1,345 | 1,278 |
EBIT | -3,025 | -8,269 | -6,624 | -10,399 | 2,812 | 6,910 |
EBIT Margin | -8.84% | -27.92% | -22.97% | -81.46% | 18.06% | 39.01% |
Effective Tax Rate | - | - | - | - | 64.56% | - |
Advertising Expenses | - | 384 | 2,238 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.